New stocks like this will keep it alive and well.
(SPSI) nasdaq small cap
SpectraSCIENCE currently has two issued United States patents related to the use of spectroscopy for the diagnosis of atherosclerotic cardiovascular disease, including heart disease and stroke, and the detection of cancer utilizing minimally invasive techniques. These patents augment the Company's exclusive license agreement with the Massachusetts Institute of Technology covering 31 issued and pending patents. In addition, the Company has several patents pending, including both device and method patents, for endoscopic and laparoscopic detection of cancer. SpectraSCIENCE's ongoing success in achieving a strong intellectual property position will both enhance the Company's technological leadership role and provide access to additional medical specialty markets in the future.
SpectraSCIENCE has met or exceeded management's objectives in several areas that are vital to the Company's future prosperity. These areas support the Company's principal strategy of leveraging the collective expertise of SpectraSCIENCE, as well as its clinical and strategic partners, in the core technologies of spectroscopy, fiber optics, computer software and hardware, and minimally-invasive medical delivery systems for the diagnosis and to facilitate treatment of a broad range of human diseases.
SpectraSCIENCE, is a market driven development-stage company, located in Minneapolis, Minnesota, which applies advanced spectroscopic diagnostic techniques to the analysis of specific human tissues associated with important diseases. The Company believes its technology will significantly impact the medical market, initially in cardiovascular medicine and the detection of cancer. |
